Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Supplemental material
  • Version history
  • Article usage
  • Citations to this article
Advertisement

ResearchIn-Press PreviewHematologyOncology Open Access | 10.1172/jci.insight.190833

Influence of Oxidation Resistance 1 on disease progression in chronic myeloid leukemia

weiqi huang,1 Bin Liu,1 Liping Hu,1 Chi-Hao Luan,2 Priyam Patel,1 Elizabeth T. Bartom,1 and Elizabeth A. Eklund1

1The Feinberg School of Medicine, Northwestern University, Chicago, United States of America

2Department of Molecular Biosciences, Northwestern University, Evanston, United States of America

Find articles by huang, w. in: PubMed | Google Scholar |

1The Feinberg School of Medicine, Northwestern University, Chicago, United States of America

2Department of Molecular Biosciences, Northwestern University, Evanston, United States of America

Find articles by Liu, B. in: PubMed | Google Scholar

1The Feinberg School of Medicine, Northwestern University, Chicago, United States of America

2Department of Molecular Biosciences, Northwestern University, Evanston, United States of America

Find articles by Hu, L. in: PubMed | Google Scholar

1The Feinberg School of Medicine, Northwestern University, Chicago, United States of America

2Department of Molecular Biosciences, Northwestern University, Evanston, United States of America

Find articles by Luan, C. in: PubMed | Google Scholar

1The Feinberg School of Medicine, Northwestern University, Chicago, United States of America

2Department of Molecular Biosciences, Northwestern University, Evanston, United States of America

Find articles by Patel, P. in: PubMed | Google Scholar

1The Feinberg School of Medicine, Northwestern University, Chicago, United States of America

2Department of Molecular Biosciences, Northwestern University, Evanston, United States of America

Find articles by Bartom, E. in: PubMed | Google Scholar |

1The Feinberg School of Medicine, Northwestern University, Chicago, United States of America

2Department of Molecular Biosciences, Northwestern University, Evanston, United States of America

Find articles by Eklund, E. in: PubMed | Google Scholar

Published November 25, 2025 - More info

JCI Insight. https://doi.org/10.1172/jci.insight.190833.
Copyright © 2025, huang et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published November 25, 2025 - Version history
View PDF
Abstract

Survival in chronic myeloid leukemia (CML) was dramatically improved by development of tyrosine kinase inhibitors (TKIs) directed to the BCR::ABL1 oncogene. Unfortunately, ~30% of CML patients develop TKI-resistance during prolonged treatment, with enhanced blast crisis risk. Oxidation Resistance 1 (Oxr1) regulates anti-oxidant pathways that detoxify reactive oxygen species (ROS) generated by the phagocyte-NADPH oxidase. In the current studies, we found that Oxr1 expression increased in hematopoietic stem and progenitor cells (HSPCs) from CML mice versus controls; decreased during TKI-induced remission; and rose during chronic phase relapse. Oxr1 has long and short isoforms, and we found increased short, but decreased long, Oxr1 in mice or humans during CML relapse. We determined long Oxr1 prevents ROS accumulation in CML marrow, but short Oxr1 is a dominant negative. Previously, we found exaggerated and sustained emergency granulopoiesis in CML mice, with repeated episodes facilitating relapse during TKI-remission. In the current studies, we found knocking-down Oxr1 in murine marrow further accelerates CML progression during this physiologic stress. We found increased DNA-damage in HSPCs from these mice, including a BCR::ABL1 kinase-domain mutation found in TKI-resistant human CML. These studies suggest long Oxr1 detoxifies ROS to decrease mutagenesis in CML, but aberrant short Oxr1 expression enhances progression.

Supplemental material

View Unedited blot and gel images

View xlsx

View

Version history
  • Version 1 (November 25, 2025): In-Press Preview

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Supplemental material
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts